Short answer

Oruka Therapeutics, Inc. (ORKA) filed its fiscal 2025 10-K annual report with the SEC on Mar 12, 2026.

Top risk flagged: FDA regulatory delays risk impacting approval timeline for product candidates ORKA-001 and ORKA-002 amid ongoing Phase 1 and Phase 2 trials

FY2025 key financial metrics · XBRL

Source: XBRL data from the Oruka Therapeutics, Inc. (ORKA) FY2025 10-K on SEC EDGAR. USD.

AI summary of each section, grounded in the filing text

Core business: Clinical-stage biopharma developing novel monoclonal antibodies for psoriasis and inflammatory/immunology indications
New emphasis: Acquisition and rebranding of Pre-Merger Oruka in 2024, launching dual lead programs ORKA-001 and ORKA-002 targeting IL-23p19 and IL-17A/F
Strategic shift: Leveraging advanced antibody engineering for extended half-life, aiming for reduced dosing frequency (up to twice yearly) and improved efficacy vs standard-of-care
Quantitative highlight: Initiated multiple Phase 2 trials; ORKA-001 Phase 2a enrolled 84 patients, Phase 2b expected to enroll 160 patients; ORKA-002 Phase 2 planned to enroll 160 patients
Noteworthy fact: ORKA-001 demonstrated ~100-day half-life in Phase 1; ORKA-002 showed ~75-80 day half-life, supporting potential twice-yearly dosing schedules

No revenue generated; net loss $105.4M for 2025; accumulated deficit $189.2M as of December 31, 2025
Operating cash flow negative $88.2M; cash, equivalents, and marketable securities $479.6M at year-end
No segments reporting revenue; focus on clinical-stage pipeline with lead programs ORKA-001 and ORKA-002 in Phase 1/2 trials
Capital raised $275M in Pre-Closing Financing; $20.5M transaction costs reduce equity; no dividends or buybacks disclosed
Management expects losses to continue; Phase 2 data releases anticipated in 2026-2027; FDA timelines uncertain, key risk regulatory review duration

FDA regulatory delays risk impacting approval timeline for product candidates ORKA-001 and ORKA-002 amid ongoing Phase 1 and Phase 2 trials
Geopolitical tensions and elevated interest rates contributing to market volatility that may hinder timely capital raises for ongoing clinical development
Dependency on third-party manufacturers and single-source suppliers for drug delivery devices poses risk of supply interruptions or delayed regulatory approvals
Competitive pressure from larger biopharma firms with greater resources and existing immunology programs threatens market penetration for Oruka’s candidates
High dilution risk from recent equity raises totaling over 16 million shares and $38.9 million net proceeds under at-the-market offering through March 2026

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.